Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954552 | 0.92 | MAP3K12 (0.33) | MAP3K12TGFBR1 | |
| SCHEMBL21023747 | 0.83 | DPP4 (0.35) | TGFBR1 | |
| SCHEMBL18161187 | 0.81 | KDM5A (0.30) | — | |
| SCHEMBL19954611 | 0.79 | MPO (0.35) | MAP3K12TGFBR1 | |
| SCHEMBL19954665 | 0.79 | LMNA (0.35) | MAP3K12TGFBR1 | |
| SCHEMBL19105611 | 0.79 | TGFBR1 (0.35) | MAP3K12TGFBR1 | |
| SCHEMBL19954571 | 0.79 | NR3C2 (0.34) | MAP3K12TGFBR1 | |
| SCHEMBL19954523 | 0.79 | TGFBR1 (0.35) | MAP3K12TGFBR1 | |
| SCHEMBL19954663 | 0.76 | NR3C2 (0.38) | MAP3K12TGFBR1 | |
| SCHEMBL19954574 | 0.76 | MAP3K12 (0.43) | MAP3K12TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | LYCERA CORPORATION | 2018-08-09 | — | — | US | disclosed |
| US-9914706-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | LYCERA CORPORATION (US) | 2018-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392350-B2 | N-substituted pyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof | ATP5F1A, ATP5ME, ATP5F1D | MAP3K12 1341/4885TGFBR1 4644/4885 |
| US-20180222867-A1 | N-SUBSTITUTED PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF | ATP5F1A, ATP5ME, ATP5F1D | MAP3K12 1341/4885TGFBR1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.